Registration 333-299119
S-1MEF · 2026-09-24 · 0001193125-26-401133
Terms from the governing filing for this registration; not a claim that the offering is open today.
Company research
ADARx Pharmaceuticals, Inc.
CIK 1802369Updated Sep 26, 2026
Filing activity
Latest filing
13 filings on record · EFFECT, 3, S-1MEF, CERT, 8-A12B, S-1/A.
About the company
We are a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases. We are focused on advancing and expanding our pipeline of highly potent, selective and durable siRNA therapeutic candidates, including three clinical-stage programs and two advanced preclinical programs. Our goal is to control the expression of specific disease drivers with highly selective RNA targeted therapies, delivering life-changing treatments for patients with urgent unmet medical needs. Our team is united by a shared vision to build a leading next-generation siRNA therapeutics company.
Recent filings
Show 5 more recent filings
Offerings
Registration 333-299119
Registration 333-298782
Filing attachments
d903461dex107.htm · S-1/A · 2026-09-21
EX-10.7 7 d903461dex107.htm EX-10.7 EX-10.7 Exhibit 10.7 ADAR X P HARMACEUTICALS, I NC. N ON -E MPLOYEE D IRECTOR C OMPENSATION P OLICY Each member of the Board of Directors (the “Board”) of ADARx Pharmaceuticals, Inc. (the “Company”) who is not also serving as an employee of or consultant to the Company or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy (this “Policy”) for his or…
Read attachment ↗d903461dex41.htm · S-1/A · 2026-09-14
EX-4.1 2 d903461dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 INCORPORATED UNDER THE CUSIP XXXXXX XX X LAWS OF THE STATE SEE REVERSE FOR CERTAIN OF DELAWARE DEFINITIONS AND LEGENDS This certifies that BY: COUNTERSIGNED is the record holder of AND EQUINITI FULLY PAID AND NONASSESSABLE SHARES OF COMMON STOCK, $0.0001 PAR VALUE PER SHARE, OF ADARX PHARMACEUTICALS, INC. TRUST transferable on the books of the Corporation in person or by duly authorized attorney upon surrender of this Certificate properly…
Read attachment ↗d903461dex42.htm · S-1 · 2026-09-04
EX-4.2 6 d903461dex42.htm EX-4.2 EX-4.2 Exhibit 4.2 THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 2nd day of August, 2023, by and among ADARx Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”. RECITALS WHEREAS, certain of the Investors (the “Existing I…
Read attachment ↗